P
Petri Bono
Researcher at University of Helsinki
Publications - 184
Citations - 17297
Petri Bono is an academic researcher from University of Helsinki. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 48, co-authored 171 publications receiving 15170 citations. Previous affiliations of Petri Bono include Massachusetts Institute of Technology & Aarhus University.
Papers
More filters
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu,Pirkko-Liisa Kellokumpu-Lehtinen,Petri Bono,Tuomo Alanko,Vesa Kataja,Raija Asola,Tapio Utriainen,R. Kokko,Akseli Hemminki,Maija Tarkkanen,Taina Turpeenniemi-Hujanen,Sirkku Jyrkkiö,Martti Flander,Leena Helle,Seija Ingalsuo,Kaisu Johansson,Anna-Stina Jääskeläinen,Marjo Pajunen,Mervi Rauhala,Jaana Kaleva-Kerola,T. Salminen,M. Leinonen,Inkeri Elomaa,Jorma Isola +23 more
TL;DR: A short course of trastuzumab administered concomitantly with docetaxel or vinorelbine is effective in women with breast cancer who have an amplified HER2/neu gene.
Journal ArticleDOI
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Sherene Loi,Sherene Loi,Stefan Michiels,Stefan Michiels,Roberto Salgado,Nicolas Sirtaine,Vinu Jose,Debora Fumagalli,P-L Kellokumpu-Lehtinen,Petri Bono,Vesa Kataja,Christine Desmedt,Martine Piccart,Sibylle Loibl,Carsten Denkert,Mark J. Smyth,Heikki Joensuu,Christos Sotiriou +17 more
TL;DR: Higher levels of TILs present at diagnosis were significantly associated with decreased distant recurrence rates in primary TNBC, and an association between higher levels ofTILs and increased trastuzumab benefit in HER2+ disease is reported for the first time.
Journal ArticleDOI
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia,Jose A. Lopez-Martin,Johanna C. Bendell,Patrick A. Ott,Matthew H. Taylor,Joseph Paul Eder,Dirk Jäger,M. Catherine Pietanza,Dung T. Le,Filippo de Braud,Michael A. Morse,Paolo A. Ascierto,Leora Horn,Asim Amin,Rathi N. Pillai,Jeffry Evans,Ian Chau,Petri Bono,Akin Atmaca,Padmanee Sharma,Christopher T. Harbison,Chen Sheng Lin,Olaf Christensen,Emiliano Calvo +23 more
TL;DR: An objective response was achieved in ten (10%) of 98 patients receiving nivolumab 3 mg/kg, one (33%) of three patients receivingnivolUMab 1mg/kg plus ipilimumab 1 mg /kg, and 14 (23%) of 61 receiving n ivolumAB 1 mg/ kg plus ipILimumab 3mg/ kg, and ten (19%) of 54 receiving nvolum ab 3 mg / kg plusipilimum
Journal ArticleDOI
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Heikki Joensuu,Mikael Eriksson,Kirsten Sundby Hall,Jörg T. Hartmann,Daniel Pink,Jochen Schütte,Giuliano Ramadori,Peter Hohenberger,Justus Duyster,Salah-Eddin Al-Batran,Marcus Schlemmer,Sebastian Bauer,Eva Wardelmann,Maarit Sarlomo-Rikala,Bengt Nilsson,Harri Sihto,Odd R. Monge,Petri Bono,Raija Kallio,Aki Vehtari,M. Leinonen,Thor Alvegård,Peter Reichardt +22 more
TL;DR: Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo and overall survival of GIST patients with a high risk of Gist recurrence.